Organization (Other)
Instituto do Coração
ClinicalTrials.gov lists Instituto do Coração as lead sponsor of 17 trials. It has 11 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Instituto do Coração: 17 lead-sponsored trials and 1 legal-entity registration.
Disease areas (30)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Heart Defects, Congenital | 2 |
| Pain | 2 |
| Coronary Artery Disease | 2 |
| Coronary Disease | 2 |
| Agnosia | 1 |
Showing 5 of 30 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2012 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (11)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Ropivacaine | Agnosia | Phase 3 | 1 |
| Ropivacaine | Bites and Stings | Phase 3 | 1 |
| Standard Postoperative Analgesics | Bites and Stings | Phase 3 | 1 |
| Standard Postoperative Analgesics | Agnosia | Phase 3 | 1 |
| Optimized medical therapy | Death | Not reported | 1 |
Showing 5 of 11 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| CLONIDINE | 1 |
| TIVA | 1 |
| .spironolactone | 1 |
| SEVOFLURANE | 1 |
| Antibiotic Regimen | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 1 of 1 on time (n=1) |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarker capability evidence.
Counted at group level under Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.